Oncology Venture – Latest news

Successful inclusion in Phase 2 of LiPlaCis for metastatic Breast cancer

English
Swedish

 

LiPlaCis Phase 2: Relevant Clinical Benefits in 3 out of 5 Treated Patients

English
Swedish

 

Oncology Venture publishes Half-year Report 2017

English
Swedish

 

Oncology Venture annonces Pipeline update

See press release
Läs pressmeddelande

 

2X Oncology’s chief executive officer, George O. Elston’s letter to shareholders

Read the newsletter

 

MedWatch article from 3 August 2017

Lovende studie bringer Oncology Venture nærmere første lægemiddel (Danish)
Oncology Venture närmar sig sitt första läkemedel efter en lovande studie (Swedish)

 

Aktieinfo publishes analysis on Oncology Venture

Read the analysis (Danish only)
Read the analysis (Swedish)

 

Successful DRP prediction of patients treated with 2X-121, the PARP inhibitor from Eisai

 

 

Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121

See Press release
Läs pressmeddelande

 

Successful prediction of Cancer response to LiPlaCis in Breast cancer and other tumors by OV’s DRP

See Press release
Läs pressmeddelande

 

OV`s second drug candidate in the clinic – First Multiple Myeloma patient in study with APO010

See Press release
Läs pressmeddelande

 

2X Oncology obtains US IND for 2X-111 a Liposomal doxorubicin

See Press release
Läs pressmeddelande

 

The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by the DRP

See Press release
Läs pressmeddelande

 

2X Oncology Inc. presents at Jefferies Global Healtcare conference (live webcast)

 

Berlingske Business: Interview with CEO of Oncology Venture

Read the article

 

Interview with OV and MPI in ‘Millionærklubben’

Listen to the radio program

 

Latest articles from MedWatch (Danish)

19 January 2017: Oncology Venture får europæisk stjernebevilling

 

VD Peter Buhl video presentation at Sedermeradagen in Copenhagen 23. March

See the Video

 

Oncology Venture secures seed financing for two SPVs & DRP Exclusivity

English
Swedish

 

Oncology Venture: First DRP-positive breast cancer patient obtained reduction of tumor

English
Swedish

 

Oncology Venture: Best Practice article on APO010

Download (In Danish only)

Presentation of OV by CEO Peter Buhl Jensen

Video

 

Smallcap.se analysis of Oncology Venture

Swedish
English 

 

 

Peter Buhl Jensen talks about Oncology Venture – Radio24syv

Listen here – 10 July 2015
Listen here – 22 July 2015

Stock information

Latest (SEK)
High (SEK)
Low (SEK)
%
+/-
Volume
Amount

Updated on

 

DRP Technology Presentation

Doctor B

 

OV Company Presentation
(PDF-version)

Presentation